Market Evaluation Of Very Low Dose Glucagon (VLDG) For The Treatment Of Insulin-induced Nocturnal Hypoglycaemia

极低剂量胰高血糖素 (VLDG) 治疗胰岛素引起的夜间低血糖的市场评估

• 批准号: 700071
• 金额: $ 1.91万
• 依托单位: ARECOR LIMITED
• 依托单位国家: 英国
• 项目类别: GRD Proof of Market
• 财政年份: 2012
• 资助国家: 英国
• 起止时间: 2012 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=700071
• 关键词: Market; Evaluation; Very; Low; Dose

Arestat™ is Arecor’s protein stabilization technology. The application of Arestat™ toglucagon, a drug used in the treatment of hypoglycaemia in emergency situations, has allowedthe development of a novel aqueous dose of glucagon. The current marketed versions ofglucagon are lyophilized powders requiring reconstitution prior to administration. Thesepresentations are not in the correct format to be used as Very Low Dose Glucagon (VLDG)for the treatment of nocturnal hypoglycaemia which requires automated administration of aliquid dose in small quantities. The incidence of nocturnal hypoglycaemia in insulindependentType I diabetics is high, however, there are no VLDG products on the market totreat this condition. Arecor, therefore, are considering utilizing their novel aqueousformulation of glucagon to develop a VLDG product to address the market need. A marketresearch study which engages opinion leaders in the field is urgently required to ascertain thetechnical feasibility and commercial potential of a VLDG product.

ARSTAT™是爱可可的蛋白质稳定技术。将ARSTAT™应用于胰高血糖素，一种用于治疗紧急情况下低血糖的药物，允许开发一种新的含水剂量的胰高血糖素。目前市场上销售的胰高血糖素是冻干粉，在给药前需要重新配制。这些陈述的格式不正确，不能作为极低剂量的胰高血糖素(VLDG)用于治疗夜间低血糖，夜间低血糖需要自动给予少量液体剂量。胰岛素依赖型I型糖尿病患者夜间低血糖的发生率很高，然而，市场上还没有VLDG产品来治疗这种情况。因此，Arecor正在考虑利用他们新的水基高血糖素配方来开发VLDG产品，以满足市场需求。迫切需要一项让该领域的意见领袖参与的市场研究，以确定VLDG产品的技术可行性和商业潜力。